New streamlined notification scheme for lowest-risk clinical trials

Written By Luke Brewer

The MHRA has announced that a streamlined 14-day review will be available for the lowest risk Phase 3 and 4 trials (as per the feedback they received during the recent MHRA consultation).

You can read the full details about the launch on the MHRA website here, and view the details for how to apply for the scheme on the guidance page here (under the sub-heading ‘New notification scheme’).

Luke Brewer
Previous

Full government response to the Lord O'Shaughnessy review into commercial clinical trials
Next

NCVR October Roll-out: Update